Clinical Trials
54 trialsNCT01742299 2026-05-14
Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
Novartis
Phase 4 Completed
NCT01046487 2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1 Completed
NCT05381753 2026-02-11
Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World
CStone Pharmaceuticals
Completed
NCT06038552 2025-02-26
Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM
First Affiliated Hospital, Sun Yat-Sen University
Completed
NCT06628739 2024-10-08
Correlation Between Imatinib Trough Concentration and Efficacy in Advanced GIST Patients with Different Genotypes
First Affiliated Hospital, Sun Yat-Sen University
Completed
NCT01294202 2024-08-02
A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST
Astex Pharmaceuticals, Inc.
Phase 2 Completed
NCT01738139 2024-03-21
Ipilimumab and Imatinib Mesylate in Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02260505 2024-01-05
ImadGist
Centre Leon Berard
Phase 3 Completed
NCT04006769 2023-10-18
Entacapone Combination With Imatinib for Treatment of GIST
Xiangya Hospital of Central South University
Phase EARLY_PHASE1 Completed
NCT00161213 2023-08-14
Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer
Rutgers, The State University of New Jersey
Phase 2 Completed
NCT00764595 2023-07-21
GISTs
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase 2 Completed
NCT02712112 2023-01-04
A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs
Asan Medical Center
Phase 2 Completed
NCT03609424 2023-01-03
PDR001 Plus Imatinib for Metastatic or Unresectable GIST
Asan Medical Center
Phase 1/2 Completed
NCT03170180 2022-06-15
Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer
Samsung Medical Center
Phase 2 Completed
NCT01275222 2021-06-25
Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
Novartis
Phase 1/2 Completed
NCT00135005 2020-12-08
Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)
Novartis
Phase 1 Completed
NCT00028002 2020-10-26
Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
National Cancer Institute (NCI)
Phase 2 Completed
NCT00510354 2020-09-10
Radix
Novartis
Phase 4 Completed
NCT00867334 2020-06-30
NITMEC
Inova Health Care Services
Phase 1/2 Completed
NCT02257541 2020-03-30
BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01151852 2020-01-14
Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT
Asan Medical Center
Phase 3 Completed
NCT00278876 2020-01-07
Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation
Asan Medical Center
Phase 2 Completed
NCT00068380 2018-07-11
A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00103168 2018-07-09
Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00867113 2018-03-14
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
Novartis
Phase 2 Completed
NCT00455559 2018-02-22
Ph II Study of Perifosine Plus Gleevec for Patients With GIST
AEterna Zentaris
Phase 2 Completed
NCT01172548 2017-05-31
INV555
Novartis
Phase 2 Completed
NCT01483014 2016-11-18
CONVERT
Novartis
Phase 2 Completed
NCT00785785 2016-06-16
ENESTg1
Novartis
Phase 3 Completed
NCT00293124 2015-08-13
Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors
Central European Cooperative Oncology Group
Phase 3 Completed
NCT00030667 2015-04-15
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
National Cancer Institute (NCI)
Phase 2 Completed
NCT01267695 2015-02-03
Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
Peking University
Phase 2 Completed
NCT01751919 2014-10-01
A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)
Dong-A ST Co., Ltd.
Phase 1 Completed
NCT00237185 2014-08-19
A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene
Novartis
Phase 2 Completed
NCT02103322 2014-06-27
Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions
Amneal Pharmaceuticals, LLC
Phase 2/3 Completed
NCT00183833 2014-05-22
Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors
University of Southern California
Phase 1 Completed
NCT00041197 2013-07-16
Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT00441155 2013-05-13
Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib
Novartis
Phase 1 Completed
NCT00601510 2013-03-19
Imatinib, Capecitabine, and Cisplatin in Treating Patients With Unresectable or Metastatic Stomach Cancer
Technical University of Munich
Phase 1 Completed
NCT00025246 2013-02-20
Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00025415 2013-02-07
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed
NCT00041340 2013-01-23
Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00784446 2013-01-07
First-line Therapy of Stage IV Colorectal Cancer
University of Cologne
Phase 1/2 Completed
NCT01270984 2012-10-31
Imatinib
Chong Kun Dang Pharmaceutical
Phase 1 Completed
NCT01048320 2012-09-25
RPGOG1
Royal Marsden NHS Foundation Trust
Phase 1 Completed
NCT00006357 2012-09-24
STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1/2 Completed
NCT00171977 2012-08-07
Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)
Novartis
Phase 4 Completed
NCT00471328 2012-06-12
ENEST
Novartis
Phase 3 Completed
NCT00237172 2012-05-01
Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)
Novartis
Phase 2 Completed
NCT00112632 2012-03-08
Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
Technical University of Munich
Phase 2 Completed